PFE analyst estimates

Pfizer (PFE) analyst ratings, the average price target and its range, and every firm's latest call.

PFE analyst ratings and price targets

DateFirmCallTarget
Nov 12, 2026BernsteinBernstein SocGen Group Reiterates Market Perform Rating on Pfizer (PFE)$29.00
Nov 6, 2026FBN SecuritiesPfizer (PFE) PT Raised to $34 at Freedom Broker$34.00
Nov 4, 2026Argus ResearchPfizer (PFE) PT Raised to $40 at Argus$40.00
Oct 8, 2026Cantor FitzgeraldPfizer (PFE) PT Raised to $28 at Cantor Fitzgerald on Growing Sector Tailwinds$28.00
Oct 6, 2026ScotiabankPfizer price target raised to $33 from $30 at Scotiabank$33.00
Sep 10, 2026HSBCPfizer price target raised to $30 from $28 at HSBC$30.00
Aug 7, 2026GuggenheimPfizer price target lowered to $31 from $35 at Guggenheim$31.00
Jul 6, 2026HSBCPfizer downgraded to Hold from Buy at HSBC$28.00
May 27, 2026UBSUBS Reiterates Neutral Rating on Pfizer (PFE)$27.00
May 14, 2026Wolfe ResearchPfizer price target raised to $26 from $25 at Wolfe Research$26.00
Mar 17, 2026Morgan StanleyMorgan Stanley on Pfizer (PFE): Atirmo Ph2 data an 'incremental positive'$27.00
Mar 9, 2026BMO CapitalBMO Capital Reiterates Outperform Rating on Pfizer (PFE) following Ph2 data$30.00
Feb 24, 2026RBC CapitalRBC Capital Starts Pfizer (PFE) at Underperform$25.00
Feb 19, 2026BarclaysPfizer initiated with an Underweight at Barclays$25.00
Feb 12, 2026DaiwaPfizer downgraded to Neutral from Outperform at Daiwa$27.00